ArticleJournal of thrombosis and haemostasis : JTH2026
Human monoclonal and polyclonal anti-ADAMTS13 antibodies in immune thrombotic thrombocytopenic purpura: variable mechanisms of inhibition.
Article in Journal of thrombosis and haemostasis : JTH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pathological Allostery in ADAMTS13: Autoantibody-Induced Modulation and Its Role in Immune Thrombotic Thrombocytopenic Purpura (iTTP).Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundImmune-mediated thrombotic thrombocytopenic purpura (iTTP) is caused by antibodies, primarily immunoglobulin (Ig) Gs, that bind the plasma metalloprotease a disintegrin-like and metalloprotease with thrombospondin type 1 repeats 13 (ADAMTS13). Whether structural differences between IgG subclasses influence their mechanisms of action in iTTP or if mechanistic effects depend on pH and temperature is unknown.
objectivesTo assess how full-length antibodies and antibody subclasses mechanistically affect ADAMTS13 function, and if enzymatic assay conditions influence mechanisms.
methodsWe utilized IgG1 and IgG4 constructs derived from previously well-characterized single-chain fragments of the variable regions from patients with iTTP, plasma from patients with iTTP, and native ADAMTS13 in normal human plasma in Michaelis-Menten-based enzymatic assays in different temperature and pH conditions. ADAMTS13 antigen in patients with iTTP samples was quantified using 2 methods.
resultsADAMTS13 substrate recognition was more affected than catalytic turnover in a diagnostic condition, regardless of IgG subclass. In a more physiological condition, ADAMTS13 catalytic turnover was more affected. A mixture of effects was observed when both stimulatory and inhibitory IgG's were present, and mechanisms varied in plasma from patients with iTTP. A physiological condition yielded higher iTTP plasma ADAMTS13 activity than a routine diagnostic condition, even when antigen was low.
conclusionsWe demonstrated, for the first time, that inhibitory mechanisms depend on reaction environment and differ among patients. Results support hypotheses that IgG-mediated inhibition of ADAMTS13 may have multiple mechanisms, antigen depletion may not be the primary mode causing ADAMTS13 deficiency in most patients, and current diagnostic tools may not reflect iTTP incidence. Delineation of the clinical significance of these findings requires further studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.